Viking Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Viking Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. 

CEO
Brian Lian
CEOBrian Lian
Employees
53
Employees53
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2012
Founded2012
Employees
53
Employees53

VKTX Key Statistics

Market cap
3.91B
Market cap3.91B
Price-Earnings ratio
-10.63
Price-Earnings ratio-10.63
Dividend yield
Dividend yield
Average volume
2.59M
Average volume2.59M
High today
$33.95
High today$33.95
Low today
$32.00
Low today$32.00
Open price
$32.19
Open price$32.19
Volume
2.04M
Volume2.04M
52 Week high
$43.15
52 Week high$43.15
52 Week low
$18.92
52 Week low$18.92

Stock Snapshot

As of today, Viking Therapeutics(VKTX) shares are valued at $33.50. The company's market cap stands at 3.91B, with a P/E ratio of -10.63.

During the trading session on 2026-03-01, Viking Therapeutics(VKTX) shares reached a daily high of $33.95 and a low of $32.00. At a current price of $33.50, the stock is +4.7% higher than the low and still -1.3% under the high.

Trading activity shows a volume of 2.04M, compared to an average daily volume of 2.59M.

The stock's 52-week range extends from a low of $18.92 to a high of $43.15.

The stock's 52-week range extends from a low of $18.92 to a high of $43.15.

VKTX News

Simply Wall St 3d
Viking Therapeutics Advances VK2735 As Obesity Data And Valuation Draw Focus

Viking Therapeutics has completed enrollment in its Phase 3 VANQUISH-1 trial of VK2735, a dual GLP-1 and GIP receptor agonist for obesity. The company is advan...

Viking Therapeutics Advances VK2735 As Obesity Data And Valuation Draw Focus
Nasdaq 6d
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.

Key Points Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could...

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.

Analyst ratings

94%

of 18 ratings
Buy
94.4%
Hold
5.6%
Sell
0%

People also own

Based on the portfolios of people who own VKTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.